{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:35:36Z","timestamp":1763829336150,"version":"3.37.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III","award":["RH RH042953","SGR 01324 Q5856414G"],"award-info":[{"award-number":["RH RH042953","SGR 01324 Q5856414G"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM23\/00277"],"award-info":[{"award-number":["CM23\/00277"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Resoluci\u00f3n de la Direcci\u00f3n del Instituto de Salud Carlos III, O.A., M.P"},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III","award":["FIS PI21\/01640"],"award-info":[{"award-number":["FIS PI21\/01640"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir\/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir\/ritonavir was administered. The patient was considered to have achieved viral clearance and, thus, remdesivir was stopped, in either of these cases: (i) PCR negativity, or (ii) subgenomic RNA negativity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From January to November 2023, 18 patients benefited from a safe extended remdesivir administration, resulting in detection of SARS-CoV-2 viral clearance in a median time of 3.5 weeks (IQR 2.6\u20133.9) (min\u2013max 1.6\u20138.0). No clinical or biological side effects were detected. No patient died or needed further treatment for their COVID-19 episode.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae237","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T17:10:01Z","timestamp":1720631401000},"page":"2364-2368","source":"Crossref","is-referenced-by-count":4,"title":["Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-3889","authenticated-orcid":false,"given":"Emmanuelle","family":"Gras","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique , F75012 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso Francesco","family":"Aiello","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chumbita","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gallardo-Pizarro","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Monz\u00f3-Gallo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Teij\u00f3n-Lumbreras","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Department of Hematology, Division of Medicines, Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Division of Medicines, Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Tuset","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Medicines, Hospital Cl\u00ednic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria \u00c1ngeles","family":"Marcos","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Clinic, Universitat de Barcelona, ISGlobal , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain"},{"name":"Center for Biomedical Research in the Infectious Diseases Network (CIBER) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":false,"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain"},{"name":"Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain"},{"name":"Center for Biomedical Research in the Infectious Diseases Network (CIBER) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024090302271566200_dkae237-B1","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2468-2667(23)00079-8","article-title":"Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform","volume":"8","author":"Nab","year":"2023","journal-title":"Lancet Public Health"},{"key":"2024090302271566200_dkae237-B2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(23)00056-6","article-title":"SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry","volume":"24","author":"Cortellini","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024090302271566200_dkae237-B3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"2024090302271566200_dkae237-B4","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2021.280407","article-title":"Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19","volume":"107","author":"Garcia-Vidal","year":"2022","journal-title":"Haematologica"},{"key":"2024090302271566200_dkae237-B5","doi-asserted-by":"crossref","first-page":"826883","DOI":"10.3389\/fmicb.2022.826883","article-title":"Emergence of progressive mutations in SARS-CoV-2 from a hematologic patient with prolonged viral replication","volume":"13","author":"Garcia-Vidal","year":"2022","journal-title":"Front Microbiol"},{"key":"2024090302271566200_dkae237-B6","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae116","article-title":"Outcomes in hematopoietic cell transplant and chimeric antigen receptor T-cell therapy recipients with pre\u2013cellular therapy severe acute respiratory syndrome coronavirus 2 infection","author":"Nimgaonkar","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2024090302271566200_dkae237-B7","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","article-title":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","volume":"37","author":"Cesaro","year":"2023","journal-title":"Leukemia"},{"key":"2024090302271566200_dkae237-B8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jac\/dkad105","article-title":"Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals","volume":"78","author":"Aiello","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024090302271566200_dkae237-B9","doi-asserted-by":"crossref","first-page":"e01609-21","DOI":"10.1128\/JCM.01609-21","article-title":"Viral culture confirmed SARS-CoV-2 subgenomic RNA value as a good surrogate marker of infectivity","volume":"60","author":"Santos Bravo","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2024090302271566200_dkae237-B10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/trf.16863","article-title":"Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19","volume":"62","author":"Sanz","year":"2022","journal-title":"Transfusion (Paris)"},{"key":"2024090302271566200_dkae237-B11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/v15102066","article-title":"Remdesivir or nirmatrelvir\/ritonavir therapy for Omicron SARS-CoV-2 infection in hematological patients and cell therapy recipients","volume":"15","author":"Pi\u00f1ana","year":"2023","journal-title":"Viruses"},{"key":"2024090302271566200_dkae237-B12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s15010-023-02138-0","article-title":"Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era","volume":"52","author":"G\u00f6tz","year":"2023","journal-title":"Infection"},{"key":"2024090302271566200_dkae237-B13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024090302271566200_dkae237-B14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12985-023-02269-8","article-title":"Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir\/ritonavir and sotrovimab","volume":"20","author":"Gentile","year":"2023","journal-title":"Virol J"},{"key":"2024090302271566200_dkae237-B15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2364\/58998635\/dkae237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2364\/58998635\/dkae237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:28:10Z","timestamp":1725330490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/9\/2364\/7710615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae237","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,10]]}}}